Daiichi Sankyo Company (DSNKY) Fair Value & Analysis

Healthcare · US · Market cap $30.8B

A solid business, but screening 50% overvalued on our models.

What matters now

• The model range is unusually wide ($6.38 to $19.92). The outcome hinges heavily on assumptions, so read the point estimate with caution.
• Solid but not exceptional quality (53/100) and above fair value, neither a clear bargain nor a standout compounder.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 15, 2026.

How to read this chart

60‑month range $15.10 – $40.57 · fair‑value band $6.38 – $19.92 · the $17.57 price screens above the $8.86 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Jul 15, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Daiichi Sankyo Company (DSNKY) currently trades at $17.57, while our model-based Fair Value estimate is $8.86, implying the stock looks roughly 49.6% overvalued today. The Quality Score stands at 53/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).

Over the trailing twelve months, Daiichi Sankyo Company generated revenue of $2.1T at a net margin of 12.2%. Revenue grew 13.7% year over year. It earns a return on equity of 15.8%. The balance sheet holds a net cash position of $150B. Fundamentals as of Jul 15, 2026

Our scenario range runs from $6.38 (bear case) to $19.92 (bull case); at $17.57, the current price sits within that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 35% below its 52-week high and 17% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -25% fair-value upside, at -50%, DSNKY screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Widest divergence: Growth Earnings ($11.01) versus Asset-Based ($2.27). Highest evidence: ROIC Compounder (72).

Key figures & financial health

Quality Score breakdown

About the company

Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, the United States, Europe, and internationally.

Full company description

Daiichi Sankyo Company, Limited manufactures and sells pharmaceutical products in Japan, the United States, Europe, and internationally. The company offers Enhertu to treat patients with HER2 positive and low breast cancer, HER2 positive gastric or gastroesophageal junction adenocarcinoma, and HER2 positive solid tumors; Turalio, an oral small molecule that targets colony stimulating factor 1 receptor, KIT proto-oncogene receptor tyrosine kinase, and FMS-like tyrosine kinase 3 harboring an internal tandem duplication mutation for the treatment of symptomatic TGCT; Vanflyta, a FLT3 inhibitor to treat patients with acute myeloid leukemia; Injectafer, a ferric carboxymaltose injection for the treatment of iron deficiency; and DATROWAY to treat adult patients with breast cancer and NSCLC. It also provides Liziana and Savaysa, which are direct factor Xa inhibitors; Minnebro, Olmetec, Olmetec Plus, Rezaltas, Sevikar, and Sevikar HCT, which are antihypertensive agents; Nilemdo, an oral treatment that lowers cholesterol; Nustendi, a fixed-dose combination tablet of bempedoic acid and ezetimibe to reduce cholesterol; and Efient, an anti-platelet agent. In addition, the company offers Canalia and Tenelia for the treatment of type 2 diabetes mellitus; Emgalty and Reyvow to treat migraine attacks; Pralia for the treatment of osteoporosis of the progression of bone erosion associated with rheumatoid arthritis; Ranmark to treat bone complications and GCTB; Tarlige for the treatment of neuropathic pain; Venofer to treat iron deficiency anemia; and Vimpat, an anti-seizure medication. Further, it provides vaccines for the treatment of COVID-19, influenza infections, adsorbed cell culture-derived influenza (H5N1) influenza infections, measles/rubella infections, and mumps infections. It has a strategic collaboration with Lunit Inc. for the development of biomarker discovery and optimize translational research; Daiichi Sankyo Company, Limited has a strategic collaboration with Leica Biosystems and AstraZeneca to develop an immunohi

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2022 – FY2026 · reported fiscal years

Daiichi Sankyo Company reported revenue of $2.3T in FY2026 versus $1.0T in FY2022, a compound +21.2%/yr. Reported net income was $276B in FY2026, compounding +42.4%/yr from FY2022.

DSNKY screens 50% overvalued. Compare with Eli Lilly and Company →

Earlier news

External third-party headlines (Yahoo Finance, Reuters and others), not an editorial selection.

• Daiichi Sankyo Company reports Q1 results Seeking Alpha · Jul 31, 2026
• Daiichi Sankyo Reports First Quarter Fiscal Year 2026 Financial Results Yahoo Finance · Jul 31, 2026

Peer Group

Drug Manufacturers - General · 76 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Drug Manufacturers - General median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Drug Manufacturers - General stocks, each showing price versus our Fair Value estimate (as of Jul 15, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.